Monday, June 27, 2011

Genentech buys into Forma cancer drug program

Genentech Inc. will buy the rights to a preclinical program that zeroes in on a single cancer target from Forma Therapeutics.
Specific financial terms of the deal weren’t disclosed, but South San Francisco-based Genentech will make an upfront payment and be responsible for all development work. Genentech will have the option to buy the entire program from Forma.

No comments:

Post a Comment